About this Research Topic
Diabetes mellitus (DM) is often associated with short-term and long-term complications, including diabetic kidney disease, diabetic neuropathy, and diabetic retinopathy. In addition, type 2 DM (T2DM) and obesity are related multifactorial, complex diseases that significantly increase the risk for cardiovascular (CV) disease (CVD). Obesity plays a role in altering inflammatory and immune function, developing insulin resistance and contributing to systemic adrenergic activity, hypertension, dyslipidemia, hyperglycemia, atherosclerosis and finally, CVD. Because obesity is highly prevalent among patients with T2DM it is important to understand the relationship of weight change with CVD among these patients. The goal of therapy is to prevent the onset or progression of long-term microvascular and macrovascular complications. Tighter glycemic control, management of obesity and other cardio-renal-metabolic risk factors (RFs), and lifestyle changes have an overall benefit in managing all diabetes complications.
The goal of this Research Topic is to bring together a collection of papers on the modern non-insulin pharmacological treatment of diabetes and obesity, in the context of the integrated management using both old and new drugs, their potential in lowering glycemia and preventing microvascular complications, as well as complications from the spectrum of cardio-renal-metabolic continuum.
We welcome the submission of manuscripts including, but not limited to, the following topics:
• non-insulin pharmacotherapies for the treatment of T2DM and its complications,
• pharmacotherapies for the treatment of obesity and its complications,
• comprehensive multimodal pharmacological approaches in the treatment of obesity in T2DM patients, using wide/spectrum of old and new non-insulin drugs
• pharmacological approaches for the integrated management of diabetic complications using old and new drugs
Submissions from researchers and clinicians in endocrinology, cardiology, nephrology, internist, biochemistry, neurologist, and related disciplines are encouraged.
State-of-the-art reviews, research articles, mini reviews, case reports and opinions will be considered.
The goal of this Research Topic is to bring together a collection of papers on the modern non-insulin pharmacological treatment of diabetes and obesity, in the context of the integrated management using both old and new drugs, their potential in lowering glycemia and preventing microvascular complications, as well as complications from the spectrum of cardio-renal-metabolic continuum.
We welcome the submission of manuscripts including, but not limited to, the following topics:
• non-insulin pharmacotherapies for the treatment of T2DM and its complications,
• pharmacotherapies for the treatment of obesity and its complications,
• comprehensive multimodal pharmacological approaches in the treatment of obesity in T2DM patients, using wide/spectrum of old and new non-insulin drugs
• pharmacological approaches for the integrated management of diabetic complications using old and new drugs
Submissions from researchers and clinicians in endocrinology, cardiology, nephrology, internist, biochemistry, neurologist, and related disciplines are encouraged.
State-of-the-art reviews, research articles, mini reviews, case reports and opinions will be considered.
Keywords: Diabetes mellitus, obesity, type 2 diabetes
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
